Sanofi Zooms on Reported Delay for Lilly Blood Thinner
JGrimes
The prescription blood-thinner market is largely a zero-sum game. That explains why shares of Sanofi-Aventis — which sells the popular blood-thinner Plavix — are up more than 7% today in European trading, after reports late yesterday of a delay for a would-be rival.
The rival is prasugrel, which is being developed by Eli Lilly […]